Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968890 | 0.88 | ADRB1 (0.37) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL966632 | 0.78 | ADRB2 (0.33) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL18192908 | 0.76 | APLNR (0.34) | — | |
| SCHEMBL934564 | 0.76 | SLC18A3 (0.38) | LMNA | |
| SCHEMBL7184756 | 0.75 | HRH3 (0.35) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL13451176 | 0.74 | CYP3A4 (0.42) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL23231419 | 0.73 | LMNA (0.44) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL8282358 | 0.73 | LMNA (0.44) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL970440 | 0.71 | HPGD (0.35) | ADRB3 | |
| SCHEMBL3195970 | 0.71 | ADRB1 (0.39) | ADRB1ADRA2AADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | ADRB1 1458/4885ADRA2A 3713/4885ADRB3 2547/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | ADRB1 1458/4885ADRA2A 3713/4885ADRB3 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.